The main ICIs studied in both monotherapy and combination therapy in BC primarily target PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, and TIGIT molecules that typically suppress immune responses [19, 102–104]. This evidence concerns the gene HAVCR2 and breast cancer.